19P - OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer
|Date||08 May 2014|
|Session||Welcome reception and Poster Walk|
|Topics|| Breast Cancer
|Citation||Annals of Oncology (2014) 25 (suppl_1): i5-i7. 10.1093/annonc/mdu065|
T. Karn1, N. Sänger1, E. Ruckhäberle2, G. Bianchini3, V. Müller4, A. Rody5, E.F. Solomayer6, T. Fehm2, U. Holtrich1, S. Becker1
The RANK/RANKL/OPG pathway is well known for bone destruction in skeletal metastases but has also been implicated in osteoclast-independent roles in tumorigenesis and de novo metastasis. Experimental data suggest contribution of progesterone to tumorigenesis may be mediated by RANKL. Importantly, modulation of this pathway became possible through the availability of denosumab, an artificial counterpart of OPG, but significant gaps remain in the translation of preclinical findings on the pathway. We analyzed gene expression of RANK, RANKL and OPG from 40 Affymetrix datasets encompassing 4467 primary breast cancers and focused on ER positive disease.
We did not observe a significant prognostic value of RANK and RANKL mRNA expression. In contrast, OPG was associated with a better prognosis among 1941 ER positive cancers (HR 0.64, 95 CI 0.530.77; P